Gut Dysfunction and Non-alcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Microbiome Research
• Metabolic Disease

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a global health concern, progressing from hepatic steatosis to severe liver conditions.
• NAFLD pathogenesis is complex, involving immune and metabolic pathways, with growing recognition of the gut microbiome's role.
• Gut microbiota signals are increasingly linked to obesity and metabolic disorders like NAFLD.

Purpose of the Study:

• To review the current understanding of the gut microbiome's association with NAFLD.
• To highlight the specific bacterial signatures observed in NAFLD patients.
• To assess the potential of gut microbiome modulation as a therapeutic strategy for NAFLD.

Main Methods:

• Literature review of pre-clinical and human studies on NAFLD and gut microbiota.
• Analysis of studies identifying specific bacterial species and metabolites in NAFLD patients.
• Evaluation of evidence for the therapeutic potential of microbiome interventions.

Main Results:

• NAFLD is characterized by a distinct gut microbiome signature, with an increase in pro-inflammatory bacteria (e.g., Proteobacteria, *Escherichia coli*) and a decrease in protective bacteria (e.g., *Faecalibacterium prausnitzii*).
• Bacterial metabolites and secondary bile acids produced by the gut microbiota contribute to NAFLD-associated metabolic dysfunction.
• Pre-clinical models show germ-free mice are protected from obesity and hepatic steatosis, supporting the microbiome's influence.

Conclusions:

• The gut microbiome plays a significant role in NAFLD development and progression.
• While specific microbial alterations are identified, robust clinical evidence demonstrating the benefit of microbiome-targeted therapies for NAFLD is currently lacking.
• Further preclinical and clinical research is essential to validate the therapeutic relevance of the gut microbiota in managing NAFLD.